Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients

The aim of this study was to evaluate the impact of white blood cell (WBC) counts at presentation on the achievement of deep molecular response. A total of 362 newly diagnosed chronic-phase chronic myeloid leukemia patients (CML-CP) receiving 400 mg/day imatinib were serially monitored for a median...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Ya-Zhen, Jiang, Qian, Jiang, Hao, Lai, Yue-Yun, Zhu, Hong-Hu, Liu, Yan-Rong, Jiang, Bin, Huang, Xiao-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718283/
https://www.ncbi.nlm.nih.gov/pubmed/26765457
http://dx.doi.org/10.1097/MD.0000000000002486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718283/
https://www.ncbi.nlm.nih.gov/pubmed/26765457
http://dx.doi.org/10.1097/MD.0000000000002486

Ejemplares similares